<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171728</url>
  </required_header>
  <id_info>
    <org_study_id>1200.4</org_study_id>
    <nct_id>NCT02171728</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Open Label Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Investigation of maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamic
      parameters, and efficacy of BIBW 2992
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of BIBW 2992</measure>
    <time_frame>up to 168 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and intensity of Adverse Events according to Common Terminology Criteria (CTC version 3)</measure>
    <time_frame>up to 23 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) for several time points</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose plasma concentration</measure>
    <time_frame>Predose on day 8, 15, 22 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at 24 h following the first (C24,1) and the Day 27 dose (C24,27)</measure>
    <time_frame>24 hours after drug administration on day 24 and 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at 3 h following the first dose (C3,1)</measure>
    <time_frame>3 hours after the first dose on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration at steady state on Day 27 (Cmax,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum plasma concentration at steady state on Day 27 (tmax,ss)</measure>
    <time_frame>up to 24 hours after drug administration on day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life at steady state (t1/2,ss)</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time after oral administration at steady state (MRTpo,ss)</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance at steady state (CL/F,ss)</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss)</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor responses</measure>
    <time_frame>up to 23 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of EGFR (epidermal growth factor receptor), HER2, estrogen receptor (ER) and progesterone receptor (PrR) immunohistochemical status as based on tumor biopsies, or excisions obtained prior to this trial, with objective tumor responses</measure>
    <time_frame>up to 23 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BIBW 2992</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <arm_group_label>BIBW 2992</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with confirmed diagnosis of advanced, non-resectable and/or
             metastatic solid tumors, of types historically known to express EGFR and/or HER2
             (Human Epidermal Growth Factor Receptor), who have failed conventional treatment, or
             for whom no therapy of proven efficacy exists, or who are not amenable to established
             forms of treatment preferably patients with breast, colorectal or prostate cancer

          -  Age 18 years or older

          -  Life expectancy of at least three (3) months

          -  Written informed consent that is consistent with International Conference on
             Harmonization - Good Clinical Practice guidelines

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2

          -  Patients recovered from any therapy-related toxicities from previous chemo-, hormone-,
             immuno-, or radiotherapies to CTC &lt;=Grade 1

          -  Patients must be recovered from previous surgery

        The 12 additional patients recruited at the MTD must also meet the following criteria:

          -  Measurable tumor deposits (RECIST) by one or more techniques (X-ray, CT, MRI) and/or
             recognized tumor markers such as prostate-specific antigen (PSA) (prostate cancer) or
             cancer antigen (CA) 125 (ovarian cancer)

        Exclusion Criteria:

          -  Active infectious disease

          -  Gastrointestinal disorders that may interfere with the absorption of the study drug or
             chronic diarrhea

          -  Serious illness or concomitant non-oncological disease considered by the investigator
             to be incompatible with the protocol

          -  Patients with untreated or symptomatic brain metastases. Patients with treated,
             asymptomatic brain metastases are eligible if there has been no change in brain
             disease status for at least eight (8) weeks, no history of cerebral edema or bleeding
             in the past eight (8) weeks and no requirement for steroids or anti-epileptic therapy

          -  Cardiac left ventricular function with resting ejection fraction CTC &gt;=Grade 1

          -  Absolute neutrophil count (ANC) less than 1500/mm3

          -  Platelet count less than 100 000/mm3

          -  Bilirubin greater than 1.5 mg /dl (&gt;26 μmol /L, SI unit equivalent)

          -  Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than
             three times the upper limit of normal (if related to liver metastases greater than
             five times the upper limit of normal)

          -  Serum creatinine greater than 1.5 mg/dl (&gt;132 μmol/L, Système Internationale unit
             equivalent)

          -  Women and men who are sexually active and unwilling to use a medically acceptable
             method of contraception

          -  Pregnancy or breast-feeding

          -  Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy
             or hormone therapy (excluding Luteinizing Hormone-Releasing Hormone (LHRH) agonists,
             or other hormones taken for breast cancer, or bisphosphonates), or participation in
             another clinical study within the past four weeks before start of therapy or
             concomitantly with this study

          -  Treatment with an EGFR- or HER2 inhibiting drug within the past four weeks before
             start of therapy or concomitantly with this study (eight weeks for trastuzumab)

          -  Patients unable to comply with the protocol

          -  Active alcohol or drug abuse

        A patient may be eligible for re-treatment after the previous course is finished. A patient
        will not be eligible if any of the following conditions are met:

          -  Patients with clinical signs of disease progression or if latest X-ray, CT or MRI
             reveals disease progression

          -  Cardiac left ventricular function CTC Grade ≥ 2 at any time during the previous course

          -  Patients fulfilling any of the Exclusion Criteria (except criterion 5) listed before
             as determined

               -  On Day 28 of treatment period 1 or on Visit R1 of the current course when patient
                  is entering the repeated treatment period (treatment period 2),

               -  On Visit R5 of the previous course or on Visit R1/C1 of the current course when
                  patient is in repeated treatment period (treatment courses 3 to 6) or when
                  entering continuous treatment period (treatment course 7), or

               -  On Visit C3 of the previous course or Visit C1 of the current course when patient
                  is in continuous treatment period (treatment courses 8 to final discontinuation)

          -  Patient not recovered from any dose-limiting toxicity (DLT) 14 days after the last
             administration of BIBW 2992 in the previous course. Recovery is defined as return to
             baseline level or CTC Grade 1, whichever is higher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

